Insider buying last 90 days
No open-market insider purchases were filed for EHC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every EHC insider filing, plotted on the chart in Gekko.Open EHC in Gekko
NYSE: EHC
Encompass Health (EHC) Stock Analysis & Forecast
Sep 28 close
$124.02+0.55 (+0.4%)
Gekko Brief
AI summaryRaymond James assumed coverage on Encompass Health with a Strong Buy rating and a $150.00 price target, part of a run of positive attention this week that also included an upgrade to Buy. Alongside the analyst moves, the company announced expansion plans in Montgomery County, Texas, near Houston, including its first small-format inpatient rehabilitation hospital in Conroe and a 60-bed replacement facility in The Woodlands.
EHC closed at $124.02, up 0.4%, sitting above both its 50-day average of $119.67 and 200-day average of $107.90, with the 50-day above the 200-day. The stock's one-month return stands at 3.7% and its three-month return at 22.9%, with a 52-week high of $127.99. The GekkoIndex reads 50.6, placing it in the Neutral zone, while the price sits 7.6% above the Gekko Fair Value of $115.27.
The next earnings date falls on 28 October 2026, 29 days away and outside a typical 20-trading-day holding window. No insider, Congress or unusual options activity appears in their respective windows, and billionaire holders stand at zero versus one trailblazer holder. Seasonality over the next 20 trading days has averaged -2.4% across 5 years, rising in 2 of them. Analyst consensus from 9 firms remains unanimously at Buy, with a consensus target of $148.17, implying 19.5% upside from current levels.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Encompass Health price vs fair value
Close $124.02200-day averageGekko Fair Value $115.27
Encompass Health quick facts
- Market cap
- $12.30B
- P/E ratio
- 20.6
- Forward P/E
- 18.9
- EPS, TTM
- $5.99
- Revenue, TTM
- $6.21B
- Profit margin
- 10%
- Dividend yield
- 0.62%
- Beta
- 0.61
- Volume
- 986,498 avg 833,980
- 1-year return
- −1.3%
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±5%
- 50-day average
- $119.67
- 200-day average
- $107.90
- Next earnings
- Oct 28
- Shares outstanding
- 98.65M
Encompass Health swing-trade checklist
Encompass Health scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $124.02 is above the 50-day ($119.67) and 200-day ($107.90) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
50.6, Neutral
Reading 50.6 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
7.6% above
Price is 7.6% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 29 days
Next report Oct 28, 2026, 29 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−2.4% on average
From this point in the calendar, the next 20 trading days averaged −2.4% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Encompass Health stock chart and price history
Encompass Health closed at $124.02 on Sep 28, 2026, −1.3% over the past year, inside a 52-week range of $92.77 to $127.99.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +3.7%
- 3 months
- +22.9%
- 6 months
- +27.1%
- 1 year
- −1.3%
The full EHC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open EHC in Gekko
Follow Encompass Health through every session
Put EHC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track EHC in GekkoFree for 7 days. No credit card required.
About Encompass Health
Encompass Health treats patients recovering from major medical events, working with them either inside its own facilities or at their place of residence. It has built recognition for guiding recovery from conditions like stroke, neurological disease, heart and lung ailments, brain and spinal injuries, difficult orthopedic cases, and limb loss, with programs structured for both overnight stays and outpatient visits.
Its business splits into two branches. One centers on rehabilitation for patients needing intensive, supervised recovery after a serious diagnosis. The other, focused mainly on the Southeast and Texas, brings Medicare-certified home health offerings to adult patients, covering skilled nursing, social work support, aide services, and physical, occupational, and speech therapy, plus hospice care that comforts dying patients and their loved ones in a home setting.
The company got its start in 1983 and keeps its headquarters in Birmingham, Alabama. It once operated under the name HealthSouth Corporation, adopting the Encompass Health identity in January 2018. Its stock trades on the NYSE under the ticker EHC.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- encompasshealth.com
Encompass Health GekkoIndex: the smart money zone
Encompass Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.6, in the Neutral zone, down 5.1 points over five sessions.
50.6Neutral
Down 5.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 40 | +0.6% | +5.6% | ||
| Accumulation | 130 | +0.9% | +3.2% | ||
| Neutral (current zone) | 461 | +0.5% | +1.2% | ||
| Distribution | 40 | −1.5% | +0.5% | ||
| Selling | 1 | Too few readings yet | |||
Average EHC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the EHC price, zone by zone.Track EHC in Gekko
Is Encompass Health stock overvalued? Gekko Fair Value
Encompass Health trades 7.6% above Gekko Fair Value of $115.27, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Encompass Health shares are worth, recalculated every trading day.
$115.27
Gekko Fair Value, Sep 29, 2026
7.6% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open EHC in Gekko
Encompass Health insider and Congress trading
No open-market insider purchases were filed for Encompass Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in EHC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for EHC, plotted on the chart in Gekko.Open EHC in Gekko
Buybacks
Encompass Health has been buying back its own shares.
- Latest authorization
- $1.00B, Aug 5, 2026
- Bought back, quarter ended Jun 30, 2026
- $74.20M
- As a share of market cap
- 0.60%
- Trailing four quarters
- $247.1M
From company filings.
Hedge funds and billionaires quarter ended Dec 31
1of the funds Gekko tracks holds EHC.
1added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Encompass Health earnings: next date and track record
Encompass Health reports on Oct 28, 2026 (29 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Oct 28, 2026
29 days away
- EPS estimate
- $1.38
- Revenue estimate
- $1.60B
8 of 8reports beat the EPS estimate
±7.2%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Apr 30, 2026 AI summary
- What they said
- Encompass Health reported Q1 2026 revenue growth of 9% and adjusted EBITDA growth of 11.2%, prompting a guidance raise for full year 2026. Clinical quality metrics improved year-over-year, with discharge community rate reaching 84.5%. RN turnover hit a historic low of 17.8%, driving a 9.4% decline in premium labor spend. The company opened one new 49-bed hospital and added 44 beds, with 7 more hospitals and 340 beds planned for the remainder of 2026.
- Guidance
- Management raised full-year 2026 guidance based on Q1 outperformance. Beyond 2026, the pipeline includes 11 announced hospitals with 520 beds, plus at least one small-format hospital planned for 2027.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Apr 30, 2026 | $1.60 est $1.49 | $1.59B est $1.57B | +4.7% |
| Feb 5, 2026 | $1.46 est $1.30 | $1.54B est $1.54B | +10.2% |
| Oct 29, 2025 | $1.23 est $1.19 | $1.48B est $1.54B | −7.5% |
| Aug 4, 2025 | $1.40 est $1.23 | $1.46B est $1.43B | +4.9% |
| Apr 24, 2025 | $1.37 est $1.19 | $1.46B est $1.43B | +12.6% |
| Feb 6, 2025 | $1.17 est $1.02 | $1.41B est $1.38B | −2.3% |
| Oct 28, 2024 | $1.03 est $0.94 | $1.35B est $1.38B | +7.0% |
| Aug 5, 2024 | $1.11 est $1.01 | $1.30B est $1.30B | −8.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Encompass Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Encompass Health is $148.17, +19.5% from the last close, from 9 firms rating the stock in the last 90 days.
$148.17consensus 12-month target, +19.5% from the last close
Now $124.02Avg $148.17
Low $140High $155
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | Raymond James | $150 | +20.9% |
| Sep 18 | Deutsche Bank | $142 | +14.5% |
| Sep 17 | KeyBanc | $147 | +18.5% |
| Aug 9 | TD Cowen | $140 | +12.9% |
| Aug 7 | Truist Financial | $150 | +20.9% |
+1.2%average 20-day move after past Neutral readings
−2.4%average move over the next 20 trading days in the last 5 years
±2.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Encompass Health seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Encompass Health averaged −2.4% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.3% | 1 of 5 |
| Next 10 trading days | −3.5% | 1 of 5 |
| Next 15 trading days | −1.6% | 2 of 5 |
| Next 20 trading days | −2.4% | 2 of 5 |
| Next 30 trading days | +0.3% | 2 of 5 |
For scale, EHC’s typical 20-trading-day move in either direction is about 5%.
Encompass Health market cap and key statistics
Encompass Health’s market cap is $12.30B, with a P/E ratio of 20.6 and revenue of $6.21B over the last twelve months.
Valuation
- Market cap
- $12.30B
- P/E ratio
- 20.6
- Forward P/E
- 18.9
- EPS, TTM
- $5.99
- Gekko Fair Value
- $115.27
Trading
- Volume
- 986,498
- Avg volume, 20 days
- 833,980
- 52-week high
- $127.99
- 52-week low
- $92.77
- Shares outstanding
- 98.65M
Financials
- Revenue, TTM
- $6.21B
- Profit margin
- 10%
- Return on equity
- 25%
- Quarterly earnings growth, YoY
- +10.8%
Risk and income
- Beta
- 0.61
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±5%
- Dividend yield
- 0.62%
Encompass Health stock news this week
Coverage of Encompass Health this week reads positive: 3 positive, 0 neutral and 0 negative headlines.
- Raymond James assumes coverage on Encompass Health stock with Strong Buy ratingInvesting.com, Sep 28
- Encompass Health Adds New Capacity With First Small-Format HospitalZacks Investment Research, Sep 25
- Encompass Health plans two hospitals in Montgomery County, Texas By Investing.comInvesting.com Nigeria, Sep 24
- Encompass Health expands in Montgomery County, Texas, with first small-format hospital, replacement hospitalPR Newswire, Sep 24
- Encompass Health (EHC) Upgraded to Buy: Here's WhyZacks Investment Research, Sep 24
Encompass Health peers
Encompass Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Accumulation | 3.9% below |
| GHGuardant Health | Neutral | 0.5% above |
| SOLVSolventum | Neutral | 16.4% below |
| DVADaVita | Accumulation | 15.9% below |
| BTSGBrightSpring Health Services | Accumulation | 7.4% below |
| ENSGEnsign | Neutral | 11.2% above |
A peer links to its own page where one exists.
Encompass Health stock FAQ
What is Encompass Health’s market cap?
Encompass Health’s market cap is $12.30B at the Sep 28, 2026 close of $124.02, with 98.65M shares outstanding. The shares trade on a P/E ratio of 20.6.
What is the Encompass Health stock forecast?
The consensus analyst 12-month price target for Encompass Health is $148.17, +19.5% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Encompass Health stock overvalued or undervalued?
On Gekko’s estimate Encompass Health is overvalued: the Sep 28, 2026 close of $124.02 is 7.6% above Gekko Fair Value of $115.27. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Encompass Health report earnings next?
Encompass Health is expected to report on Oct 28, 2026 (29 days away). Analysts expect earnings of $1.38 per share on revenue of $1.60B. Encompass Health beat the earnings estimate in 8 of its last 8 reports, moving 7.2% on average across the report.
What is Encompass Health’s 52-week high and low?
Encompass Health’s 52-week high is $127.99 and its 52-week low is $92.77; it closed at $124.02 on Sep 28, 2026, −1.3% over the past year.
Is Encompass Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Encompass Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.